Prognostic Implications for High Expression of MiR-25 in Lung Adenocarcinomas of Female Non-smokers

Xu, Fanghua; Su, Yue; Zhang, Huan; Kong, Jinyu; Yu, Herbert; Qian, Biyun

doi:10.7314/apjcp.2014.15.3.1197

Cited by 33 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that miR-25 is able to regulate various developmental and cellular processes, and is implicated in a number of human diseases (31)(32)(33). miR-25 is known to be important in several types of cancer, including hepatocellular carcinoma, and colon, gastric and lung cancer (34)(35)(36). miR-25 has been indicated to be involved in various cellular processes, including cell proliferation, apoptosis and the release of cytokines (37)(38)(39)(40).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of microRNA-25 by tumor necrosis factor α is critical in the modulation of vascular smooth muscle cell proliferation

Zhi

Zhang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Atherosclerosis and coronary heart disease are characterized by a hyperplastic neointima and inflammation involving cytokines, such as tumor necrosis factor-α (TNF-α). TNF-α is pleiotropic and mediates inflammation and proliferation in various cell types, such as vascular smooth muscle cells (VSMCs). The molecular mechanism for the pleiotropic effects of TNF-α has not previously been fully elucidated. The current study identified that the expression of microRNA-25 (miR-25), a small noncoding RNA, was reduced in response to TNF-α signaling in VSMCs. Restored miR-25 expression inhibited cell proliferation and Ki-67 expression. The present study indicated that cyclin-dependent kinase 6 (CDK6) was the direct target gene of miR-25 using mRNA and protein expression analysis, and luciferase assays. It was also observed that restored CDK6 expression in the miR-25 mimic-treated VSMCs partly reduced miR-25-mediated VSMC proliferation. In conclusion, miR-25 is suggested to be important in TNF-α-induced abnormal proliferation of VSMCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of microRNA-25 by tumor necrosis factor α is critical in the modulation of vascular smooth muscle cell proliferation

Zhi

Zhang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…A previous study had revealed that miR-25 expression might be associated with tumor progression and had prognostic implications in female lung adenocarcinoma patients (Xu et al 2014). In three NSCLC cell lines, H520, H460, and A549, the miR-25 expression is dramatically increased to about 10-fold when compared with that in the normal fetal lung fibroblast cell line MRC5 (Yang et al 2015).…”

Section: Discussionmentioning

confidence: 93%

Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3

Chen

Meng

et al. 2015

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

The non-small-cell lung cancer (NSCLC) is the most common type of lung cancer that affects the human health. But, the underlying mechanisms and effective therapy are still absent. MicroRNAs (miRNAs) are small RNAs that specifically bind to the 3' untranslated region (3'UTR) of its target and regulate the protein level of the target at post-transcriptional level. A lot of miRNAs had been found abnormally regulated in the NSCLC patients, and understanding their specific roles in the pathogenesis of NSCLC will help us to develop novel therapeutic approaches. Here, we reported that miR-25 is dramatically upregulated in NSCLC tissues and negatively correlated with RGS3 protein. A conserved binding sequence in the 3'UTR of RGS3 gene to miR-25 was identified, and overexpression of miR-25 induces the RGS3 inhibition. Importantly, suppression of miR-25 facilitates the cell apoptosis and retards the cell proliferation in A549 and H520 cell lines. Our data provide a novel miR-25/RGS3 signal in the development of lung cancer.

show abstract

“…Downregulation of miR-25 may increase cisplatin sensitivity and suppress the growth of NSCLC cells in vivo (51). Furthermore, increased miR-25 expression has been associated with poor OS in non-smoking females with LAC (52). The results of the present study demonstrate that miR-25 is significantly upregulated in the blood plasma of patients with LAC in the non-benefit group compared with the benefit group, and that high plasma miR-25 expression is associated with decreased PFS.…”

Section: A B C Dmentioning

confidence: 99%

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Pemetrexed combined with platinum is a first-line therapy used to treat patients with advanced non-small cell lung cancer (NSCLC) that exhibit negative or unknown epidermal growth factor receptor (EGFR) mutational status or anaplastic lymphoma kinase (ALK) rearrangements. Lung adenocarcinoma (LAC) is the primary type of NSCLC. In order to prevent overtreatment, it is necessary to identify patients with LAC who may not benefit from certain chemotherapies. Patients recruited in the present study (n=129) were diagnosed with advanced LAC and received first-line pemetrexed and platinum-based chemotherapy. A microRNA (miR) microarray was used to screen the plasma miR expression profiles in a screening set of eight patients prior to and following treatment. Specifically, plasma miR-25, miR-21, miR-27b, miR-326, miR-483-5p and miR-920 were selected for reverse transcription-quantitative polymerase chain reaction analysis in a training set (n=44) prior to treatment. The screening and training set patients were all non-smokers with no prior history of serious or chronic disease. The ∆∆Cq values of these miRs were compared between the group that showed benefit from pemetrexed and platinum treatment and the group that did not. Consequently, the ∆∆Cq values of miR-25, miR-21, miR-27b and miR-326 were further determined in a validation set (n=77). The results of the present study demonstrate that plasma expression levels of miR-25, miR-21, miR-27b and miR-326, in the training and validation sets prior to treatment, were significantly different between the benefit and non-benefit groups (P≤0.001). The expression of miR-25, miR-21, miR-27b and miR-326 was upregulated in the non-benefit group and this elevation was positively correlated with decreased progression-free survival (PFS; P≤0.001). In addition, the predictive power of each miR was evaluated through receiver operating characteristic curves, in which miR-25 exhibited the highest degree of accuracy (area under the curve, 0.926; 95% confidence interval, 0.881-0.971). These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS. Among these four miRs, miR-25 exhibited the highest degree of accuracy in predicting insensitivity, suggesting it is the most promising biomarker.

show abstract

Prognostic Implications for High Expression of MiR-25 in Lung Adenocarcinomas of Female Non-smokers

Cited by 33 publications

References 42 publications

Inhibition of microRNA-25 by tumor necrosis factor α is critical in the modulation of vascular smooth muscle cell proliferation

Inhibition of microRNA-25 by tumor necrosis factor α is critical in the modulation of vascular smooth muscle cell proliferation

Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Contact Info

Product

Resources

About